Remotely-supervised Neuromodulation in PPA
NCT: NCT07260253 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia (lvPPA), a language disorder most often caused by Alzheimer's disease. The main questions the study aims to answer are: * Is combining remotely supervised transcranial direct current stimulation (tDCS) with virtual speech-language therapy feasible and acceptable for people with lvPPA? * Does this combined treatment lead to improvements in communication compared to speech-language therapy with sham (placebo) stimulation? * Do individual brain characteristics help predict who benefits most from this treatment? Researchers will compare participants who receive active tDCS plus virtual speech-language therapy to participants who receive sham (placebo) tDCS plus virtual speech-language therapy to see if active brain stimulation enhances communication outcomes. Participants will: * Complete speech-language therapy sessions delivered by video visit. * Receive either active or sham tDCS that is remotely supervised and completed at home. * Complete language and cognitive testing before and after treatment. * Undergo brain imaging and other assessments to help understand treatment response.
Frequently Asked Questions
What is Remotely-supervised Neuromodulation in PPA?
Remotely-supervised Neuromodulation in PPA is a clinical trial registered under NCT07260253. Current status: RECRUITING.
What is the status of NCT07260253?
The current status of NCT07260253 (Remotely-supervised Neuromodulation in PPA) is: RECRUITING.
When did Remotely-supervised Neuromodulation in PPA start?
Remotely-supervised Neuromodulation in PPA started on 2026-04-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.